Mechelen, Belgium; 6 May 2015 - Galapagos NV (Euronext: GLPG) announced today that it intends to offer and sell, subject to market and other conditions, approximately $200 million of its ordinary shares in a global offering, which is comprised of an offer of ordinary shares in the form of American Depositary Shares (“ADSs”), and an offer of ordinary shares in Europe and countries outside of the United States and Canada in a concurrent private placement (the ‘global offering’). Investors other than qualified investors under applicable law will not be eligible to participate in the ordinary share private placement.
Under the global offering, Galapagos intends to grant the underwriters a 30-day option to purchase additional ordinary shares in the form of ADSs in connection with the ADS offering and a 30-day option to purchase additional ordinary shares in connection with the ordinary share private placement, up to 15% of the ordinary shares and the ADSs placed in the global offering.
The closing of the ADS offering and the ordinary share private placement taking place as part of the global offering will be conditioned on each other.
The final price per share of the ordinary shares and the ADSs placed in the global offering will be determined following the bookbuilding process.
Each of the ADSs offered in the ADS offering represents the right to receive one ordinary share.
Galapagos’ ordinary shares are currently listed on Euronext Amsterdam and Euronext Brussels under the symbol “GLPG”. Application has been made to list the ADSs to be offered in the global offering on the NASDAQ Stock Market in the United States under the symbol “GLPG”. Application will be made to admit the ordinary shares issued pursuant to the global offering to trading on Euronext Amsterdam and Euronext Brussels.
Morgan Stanley, Credit Suisse, and Cowen and Company are acting as joint book-running managers and Nomura and Bryan, Garnier & Co. are acting as co-managers for the proposed global offering. Morgan Stanley and Credit Suisse are acting as representatives of the underwriters.
A registration statement relating to the securities to be issued in the global offering has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
The securities to be issued in the global offering are to be offered only by means of a prospectus. A copy of the preliminary prospectus, when available, can be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, United States, Attention: Prospectus Department; Credit Suisse Securities (USA) LLC, One Madison Avenue, New York, NY, 10010, United States, Attention: Prospectus Department, or by telephone at +1 (800) 221-1037, or by email at newyork.prospectus@credit-suisse.com; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn’s disease. Galapagos reported good activity and a favorable safety profile at 12 weeks in both the DARWIN 1 and 2 trials in RA. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com
Help employers find you! Check out all the jobs and post your resume.
